Level of evidence for FDA drug approvals in pivotal clinical trials of hematological malignancies
- 24 January 2021
- journal article
- letter
- Published by Taylor & Francis Ltd in Leukemia & Lymphoma
- Vol. 62 (6), 1522-1524
- https://doi.org/10.1080/10428194.2021.1876872
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Participation of African American Persons in Clinical Trials Supporting US Food and Drug Administration Approval of Cancer DrugsAnnals of Internal Medicine, 2020
- Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall SurvivalJAMA Internal Medicine, 2015
- Cancer statistics, 2012CA: A Cancer Journal for Clinicians, 2012
- Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigmBlood, 2010
- The power of comparative studiesLeukemia Research, 2009
- Diversity of participants in clinical trials in an academic medical centerCancer, 2009
- The Pitfalls of Early Publication of Data in Acute Myeloid Leukemia: A Report from the Eastern Cooperative Oncology Group (ECOG).Blood, 2008